Table of Contents

company-logo

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD. Its products under the preclinical stage comprise SM17 for the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06 to treat RA, SLE, NMOSD, and SS; SM09 for the treatment of NHL and RA; and TNF2 for the treatment of autoimmune diseases. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.

SinoMab BioScience Dividend Announcement

• SinoMab BioScience does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on SinoMab BioScience dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

SinoMab BioScience Dividend History

SinoMab BioScience Dividend Yield

SinoMab BioScience current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing SinoMab BioScience stock? Use our calculator to estimate your expected dividend yield:

SinoMab BioScience Financial Ratios

P/E ratio-5.98
PEG ratio0.45
P/B ratio4.31
ROE-69.74%
Payout ratio0.00%
Current ratio1.31
Quick ratio1.31
Cash Ratio0.76

SinoMab BioScience Dividend FAQ

Does SinoMab BioScience stock pay dividends?
SinoMab BioScience does not currently pay dividends to its shareholders.
Has SinoMab BioScience ever paid a dividend?
No, SinoMab BioScience has no a history of paying dividends to its shareholders. SinoMab BioScience is not known for its dividend payments.
Why doesn't SinoMab BioScience pay dividends?
There are several potential reasons why SinoMab BioScience would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will SinoMab BioScience ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While SinoMab BioScience has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is SinoMab BioScience a dividend aristocrat?
SinoMab BioScience is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is SinoMab BioScience a dividend king?
SinoMab BioScience is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is SinoMab BioScience a dividend stock?
No, SinoMab BioScience is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy SinoMab BioScience stocks?
To buy SinoMab BioScience you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy SinoMab BioScience stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.